Bristol-Myers Squibb (BMY) Granted EC Approval for Inrebic (fedratinib) for Adult Patients with Newly Diagnosed & Previously Treated Myelofibrosis
Go back to Bristol-Myers Squibb (BMY) Granted EC Approval for Inrebic (fedratinib) for Adult Patients with Newly Diagnosed & Previously Treated Myelofibrosis| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 55.21 +0.51 (0.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.70 | 52 Week High | $77.12 | |||
| Open | $55.39 | 52 Week Low | $49.03 | |||
| Day High | $55.49 | P/E | 35.85 | |||
| Day Low | $54.96 | EPS | $1.54 | |||
| Volume | 547,605 | |||||
